Table 1.
The information of pairs of genetic alteration-driven genes and drug response genes associated with survival in breast cancer.
| Gene pairs | Genetic alterations | Univariate cox analysis | Multivariate cox analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P.value a | HR (95%CI) | P.value b | FDR | HR (95%CI) | |||||
| PARP1–ACSL1 | |||||||||
| Low or High |
PARP1: Mutation; copy number amplification; High expression ACSL1: copy number deletion; Low expression |
0.024 | 0.72(0.52–1.004) | 0.021 | 0.042 | 0.68(0.49–0.94) | |||
| PARP1–SRD5A3 | |||||||||
| Low or High |
PARP1: Mutation; copy number amplification; High expression SRD5A3: High expression |
0.0064 | 0.63(0.46–0.8794) | 0.0046 | 0.028 | 0.62(0.45–0.86) | |||
| ADIPOR2–SRD5A3 | |||||||||
| Low or High |
ADIPOR2: copy number amplification; High expression SRD5A3: High expression |
0.0034 | 0.61(0.442–0.8508) | 0.0052 | 0.028 | 0.63(0.45–0.87) | |||
| SLC39A11–SRD5A3 | |||||||||
| Low or High |
SLC39A11: copy number amplification; High expression SRD5A3: High expression |
0.0037 | 0.62(0.4434–0.8544) | 0.0092 | 0.029 | 0.65(0.47–0.90) | |||
| B3GALNT2–SRD5A3 | |||||||||
| Low or high |
B3GALNT2: copy number amplification; High expression SRD5A3: High expression |
0.013 | 0.66(0.4784–0.9172) | 0.011 | 0.029 | 0.65(0.47–0.91) | |||
| CASP12–SRD5A3 | |||||||||
| Low or High |
CASP12: copy number Deletion; Low expression SRD5A3: High expression |
0.01 | 0.65(0.4695–0.9024) | 0.018 | 0.040 | 0.67(0.48–0.93) | |||
| CDKN1C–PRLR | |||||||||
| Low or High |
CDKN1C: DNA Hypermethyation; Low expression PRLR: DNA Hypomethyation; Mutation; High expression |
0.0073 | 0.64(0.4611–0.8864) | 0.019 | 0.031 | 0.67(0.49–0.94) | |||
| PODXL2–PRLR | |||||||||
| Low or High |
PODXL2: DNA Hypomethyation; High expression PRLR: DNA Hypomethyation; Mutation; High expression |
0.015 | 0.67(0.4790.9232) | 0.031 | 0.031 | 0.70(0.50–0.97) | |||
| SLC19A1–SLC47A2 | |||||||||
| Low or High |
SLC19A1: Mutation; High expression SLC47A2: Mutation; Low expression |
0.00035 | 0.54(0.3849–0.7566) | 0.0016 | 0.032 | 0.58(0.41–0.81) | |||
| SLC19A1–SRD5A3 | |||||||||
| Low or High |
SLC19A1: Mutation; High expression SRD5A3: High expression |
0.0021 | 0.59(0.4239–0.8263) | 0.005 | 0.033 | 0.62(0.44–0.86) | |||
| AKR1C3–SLC19A1 | |||||||||
| Low or high |
AKR1C3: Mutation; Low expression SLC19A1: Mutation; High expression |
0.0018 | 0.59(0.4186–0.8199) | 0.0067 | 0.034 | 0.63(0.45–0.88) | |||
| ABCB1–SRD5A3 | |||||||||
| Low or High |
ABCB1:Mutation; Low expression SRD5A3: High expression |
0.0072 | 0.64(0.4615–0.8862) | 0.011 | 0.038 | 0.65(0.47–0.91) | |||
| PRLR–SRD5A3 | |||||||||
| Low or High |
PRLR: DNA Hypomethyation; Mutation; High expression SRD5A3: High expression |
0.012 | 0.66(0.4717–0.91) | 0.012 | 0.038 | 0.66(0.47–0.92) | |||
| NR3C2–SRD5A3 | |||||||||
| Low or high |
NR3C2: Mutation; Low expression SRD5A3: High expression |
0.0024 | 0.60(0.4335–0.8355) | 0.013 | 0.038 | 0.66(0.47–0.92) | |||
| AKR1C3–SRD5A3 | |||||||||
| Low or high |
AKR1C3: Mutation; Low expression SRD5A3: High expression |
0.0079 | 0.64(0.46–0.89) | 0.016 | 0.041 | 0.67(0.48–0.93) | |||
HR: hazard ratio.
aP.value: Univariate Cox regression analysis.
bP.value: Multivariate Cox regression analysis (including age, ER, PR, pathological stage), FDR: FDR correction for P.valueb.